VIRTUAL REALITY CUE EXPOSURE THERAPY FOR THE TREATMENT OF TOBACCO DEPENDENCE

Christopher S. Culbertson, Stephanie Shulenberger, Richard De La Garza, Thomas F. Newton and Arthur L. Brody

Researchers and clinicians have recently begun using Virtual Reality (VR) to create immersive and interactive cue exposure paradigms. The current study aimed to assess the effectiveness of individual cue exposure therapy (CET), using smoking-related VR cues (smoking-VR) as a smoking cessation treatment compared to a placebo-VR (neutral cue) treatment. The sample consisted of healthy treatment-seeking cigarette smokers, who underwent bi-weekly cognitive behavioral group therapy (CBT) plus either smoking-VR CET or placebo-VR CET (random assignment). Smoking-VR CET participants had a higher quit rate than placebo-VR CET participants (P = 0.015). Smoking-VR CET treated participants also reported smoking significantly fewer cigarettes per day at the end of treatment than placebo-VR CET treated participants (P = 0.034). These data indicate that smoking-related VR CET may prove useful in enhancing the efficacy of CBT treatment for tobacco dependence.

Keywords: Tobacco Dependence, Virtual Reality, Cognitive-behavioral Therapy, Smoking Cessation, Nicotine

INTRODUCTION

Tobacco-dependent cigarette smokers develop associations between cigarette smoking and people, places, and objects. Subsequently, these smoking-related cues generally elicit craving and induce withdrawal when presented to smokers (Abrams, Monti, Carey, Pinto, & Jacobus, 1988; R. Niaura, Abrams, Pedraza, Monti, & Rohsenow, 1992; R. S. Niaura, et al., 1988; Tiffany & Hakenewerth, 1991). This cue-induced craving propagates smoking behavior and may provoke relapse in abstinent smokers (Abrams, et al., 1988; Abrams, et al., 1987; R. Niaura, Abrams, Demuth, Pinto, & Monti, 1989; R. Niaura, Abrams, Monti, & Pedraza, 1989). Smoking cessation therapies aimed at reducing overall craving have proven successful in increasing the likelihood of quitting; however, few therapies have demonstrated success in attenuating cue-induced craving (Drummond, 2000; Ferguson & Shiffman, 2008).

Extinction learning involves the repeated presentation of a cue, previously paired with reinforcement, in the absence of that reinforcement. This process eventually ceases to elicit the originally learned behavior (Shaham, Shalev, Lu, De Wit, & Stewart, 2003). The original association between cue and reinforcement remains intact, however, and may reemerge under a number of different scenarios. Animal models have shown that reinstatement of drug-seeking to previously extinguished cues occurs upon returning to the context where drug-cue conditioning took place (renewal effect), the presentation of a drug-cue some time after extinction training (spontaneous recovery), re-exposure to the reinforcing stimulus (reinstatement), or by the cue predicting the availability of reinforcement (instrumental learning) (Self & Nestler, 1998). Each of these antecedents parallels situations reported to elicit relapse in drug-dependent individuals (Katz & Higgins, 2003), and therefore must be taken into consideration when developing behavioral therapy intended to reduce drug craving and relapse (Conklin & Tiffany, 2002).

Based on preclinical models of extinction learning, treatments have been developed to examine the efficacy of cue exposure therapy (CET) in humans (Hammersley, 1992; Heath & Bradley, 1990; Heath & Greeley, 1990). During CET, drug-dependent individuals are repeatedly exposed to drug cues (e.g., guided imagery or paraphernalia) in the absence of reinforcement (drug administration) in an attempt to extinguish previously learned drug-cue associations. Coping strategies commonly used in cognitive behavioral therapy (CBT) may also be included in CET to provide guidance on managing craving during high-risk situations (Rohsenow et al., 2001). CET has been administered in a variety of forms to treat tobacco (R. Niaura et al., 1999), alcohol- (Monti et al., 2001; Rohsenow et al., 2001), opiate- (Franken, de Haan, van der Meer, Haffmans, & Hendriks, 1999), and cocaine- (O'Brien, Childress, McLellan, & Ehrman, 1990) dependence with varying levels of success (Conklin & Tiffany, 2002).

Recently, clinicians have used Virtual Reality (VR) to create immersive and interactive cue exposure paradigms. These systems have been successfully applied to CET for the treatment of anxiety, specific phobias, posttraumatic stress (Parsons & Rizzo,
Clinical trials have shown that VR elicits significantly greater cue-induced craving than either neutral cues (Baumann & Sayette, 2006; Bordnick et al., 2004; Bordnick, Graap, Copp, Brooks, & Ferrer, 2005; Bordnick et al., 2008; Kuntze et al., 2001; J. H. Lee et al., 2003; Saladin, Brady, Graap, & Rothbaum, 2006) or traditional models of cue exposure (Kuntze et al., 2001; J. H. Lee et al., 2003). Applying immersive, multimodal VR cue exposure to appropriately spaced CET sessions may alleviate deficiencies in traditional cue exposure methods and significantly enhance the efficacy of smoking cessation treatment (Conklin & Tiffany, 2002).

The current study aimed to assess the effectiveness of individual CET, conducted with VR smoking-related cues (smoking-VR) as a smoking cessation treatment, compared to a placebo-VR treatment. To ensure that all participants received treatment for tobacco dependence, group CET was administered in combination with individual CET. We hypothesized that participants treated with smoking-VR would have higher abstinence rates and report greater reductions in craving for cigarettes than participants treated with placebo-VR.

**Materials and Methods**

**Participants**

Healthy treatment-seeking cigarette smokers (≥10 cigarettes/day), who met DSM-IV criteria for tobacco dependence, were recruited through Internet advertisements. Potential participants underwent telephone and in-person screenings. During the telephone screening, participants provided medical, psychiatric, and substance-abuse histories without personal identifiers. The in-person screenings included administration of the Smoker’s Profile, Fagerström Test for Nicotine Dependence (FTND) (Fagerstrom, 1978; Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991), Urge to Smoke (UTS) Scale (Brody et al., 2002; Jarvik et al., 2000b), and Hamilton Depression (HAM-D) (Hamilton, 1967) and Anxiety (HAM-A) (Hamilton, 1969) rating scales. Potential participants provided breath samples for measuring carbon monoxide (CO) levels using a MicroSmokerlyzer (Bedfont Scientific Ltd, Kent, United Kingdom), at the time of initial screening to verify recent smoking. All participants received detailed verbal and written descriptions of the study procedures before giving informed consent, as approved by the VA Greater Los Angeles Healthcare System Institutional Review Board.

Exclusion criteria included: 1) history of any Axis I psychiatric diagnosis other than tobacco dependence, 2) medical conditions that might interfere with treatment, 3) and current illicit drug use, except occasional marijuana use. Potential participants were required to test negative for drug use in a urine toxicology test during the in-person screening. Participants reporting recreational alcohol (≤ 1 drink/day) or marijuana (≤ 1 use/week) use, not meeting criteria for abuse/dependence, were allowed to participate, but were instructed to abstain for at least 24 h prior to each treatment session.

**Cue-Induced Craving Assessment**

Prior to the initiation of treatment, participants completed a one-hour cue-induced craving assessment. During this assessment, participants engaged in two VR sessions (smoking-VR and placebo-VR) for 10-min each with a 10-min break between sessions (presentation order was randomized between participants). Participants provided self-reports of cigarette craving prior to (time = 0), during (time = 5), after (time = 10), and following (time = 15) each VR session. Self-reports of craving were determined using the Urge to Smoke (UTS) Scale (Jarvik et al., 2000a).

**Cognitive Behavioral Therapy (CBT)**

All participants attended bi-weekly (Tuesday & Thursday) CBT group therapy sessions (60 min) over eight weeks. Participants initiated CBT on a rolling schedule following the completion of the cue-induced craving assessment. A licensed psychotherapist (S.S.) performed twelve continuous CBT sessions from a standardized manual for small groups of participants (group size varied from 2-6 participants). Participants provided self-reports of the number of cigarettes smoked the previous day and exhaled CO during each group CBT session. CBT specifically included: 1) education about smoking addiction, withdrawal, and relapse; 2) making preparations for a quit date; 3) recognizing dangerous situations (triggers) that could lead to relapse; 4) developing coping skills, such as avoiding temptation, coping with negative affective states, reducing overall stress, and distracting attention from smoking urges with other activities; and 5) social support (Abrams et al., 2003).

**Virtual Reality Cue Exposure Therapy (CET)**

Participants were randomly assigned to either smoking-VR or placebo-VR CET prior to the initiation of treatment. For CET, participants attended bi-weekly 30-min individual VR sessions prior to or following group CBT (depending on availability). The VR sessions included two 10-min exposures to VR cues (smoking-related or placebo), separated by a 10-min break. During the 10-min break, participants reviewed the coping skills taught in the most recent group CET session, and were encouraged to apply the skills during the second VR exposure. Successful completion of VR treatment required attendance of at least eight CET sessions.

The VR environments used here were constructed and presented in a similar manner to those in a previous report by our group (Culbertson et al., 2010). The smoking-VR sessions were individualized for each participant’s self-reported triggers (e.g., objects, people, places, and music associated with smoking). Varieties of environments were created and accessed using Second Life, a freely available online gaming program. These environments included a modern apartment with outdoor seating area, a driving simulation, a replica of Venice beach, a bus stop in Los Angeles, an outside area in front of a bar/restaurant, and a coffee shop. During each session, the participant navigated the VR environment from the first-person point of view while their virtual self, or avatar, smoked a virtual cigarette. Each participant’s avatar was modified to replicate his or her physical...
appearance. Additional avatars were added to each environment and modified to perform cigarette smoking animations. Other individualized smoking paraphernalia (e.g., box of preferred brand of cigarette, lighter, coffee, etc.) were also placed in each environment where possible (Figure 1).

The placebo-VR cues sessions were selected for each participant’s personal interest from a variety of settings available in Second Life. These environments included an art show, a carnival, an outdoor sports center, a space museum, and a university. Participants listened to their preferred genre of music during the placebo cue exposure. Each environment was inspected prior to participant exposure to ensure the absence of any smoking-related cues.

TREATMENT RESPONSE MEASURES: SMOKING AND CRAVING
Participants provided self-reports of smoking (cigs/day) and exhaled breath CO samples during each CET session to monitor recent smoking behavior. Abstinence was determined by a self-report of no cigarettes per day and an exhaled CO ≤ 5 ppm. Participants also provided craving ratings using the UTS scale prior to (time = 0), during (time = 15), and following (time = 30) each treatment session.

STATISTICAL ANALYSIS
Means (± standard deviations) of demographic and treatment variables were determined independently for each treatment group. Student’s t-tests and a Fisher’s exact test (for gender) were compared between treatment groups for the demographic variables. To evaluate treatment outcomes, groups were compared together, and independently, using unpaired and paired Student’s t-tests, respectively, for the primary smoking outcome measures. A Fisher’s exact test was applied to assess differences in quit rates between groups.

UTS-raw and UTS-change scores were analyzed to measure overall and cue-induced craving (craving change in response to each cue condition). The UTS-change score was calculated by subtracting the baseline rating (time = 0) for each cue condition from the following ratings (time = 5, 10, 15). This method eliminates baseline variability between participants, while also accounting for carry-over effects between cue conditions. A within-subjects general linear model (GLM) for repeated measures was used to assess the effect of cue condition and time on UTS-raw and UTS-change scores independently. An unpaired Student’s t-test was used to compare UTS-raw and UTS-change scores between cue conditions at each time point. Additionally, a Pearson correlation was determined to assess relationships between demographic and smoking characteristics, and UTS-raw and UTS-change scores.

To examine cigarette craving during treatment, a within-subject GLM for repeated measures, including a between-group variable, was used to test for interactions and/or effects of treatment type (smoking-VR and placebo-VR CET), repeated individual CET treatments (from session 1 to 8), and treatment time (time = 0, 15, 30) on self-reported UTS-raw scores. An unpaired Student’s t-test was used to assess group differences in UTS-raw scores at the start and completion of CET. A paired Student’s t-test was also used to assess the UTS-change score from the first to last CET session in all participants, and each treatment group separately. Statistical analyses were performed using SPSS 17 for Mac OS X.

RESULTS
DEMOGRAPHIC AND SMOKING CHARACTERISTICS
The study sample included craving assessment of 15 (13 men, two women) tobacco-dependent, treatment-seeking adults (mean ± SD age 42.2 ± 12.5 yr) with, on average, two years of post high school education (mean ± SD 13.8 ± 2.6 yr). Eleven participants completed treatment (smoking-VR: n = 5; placebo-VR: n = 6), and these participants reported smoking 19.8 ± 3.9 cigs/day for 20.8 ± 9.8 years, and had CO levels of 17.9 ± 12.5 prior to treatment. No significant differences were observed prior to treatment between groups on demographic or smoking characteristics (Table 1), other than the placebo-VR participants having smoked for significantly more years than smoking-VR participants (Student’s t-tests, two-tailed, P < 0.05).

CUE-INDUCED CRAVING ASSESSMENT
A within-subject GLM for repeated measures demonstrated a significant effect of cue type (smoking-VR versus placebo-VR) on self-reported UTS-raw scores (F$_{1, 14}$ = 11.19, P = 0.005) and UTS-change scores (F$_{1, 14}$ = 15.54, P = 0.001) (Figure 2). No effect of time was observed for self-reported UTS-raw or UTS-change scores. A paired Student’s t-test demonstrated that participants reported significantly greater UTS-change scores during (time = 5) (t$_{14}$ = 4.18, P = 0.001), after (time = 10) (t$_{14}$ = 3.08, P = 0.008), and following (time = 15) (t$_{14}$ = 2.76, P = 0.015) the...
smoking-VR cues, compared to the placebo-VR cues. No significant difference in UTS-raw scores was observed between cue conditions at any time point. A negative association was observed between age and UTS-raw scores during (time = 5) and following (time = 15) the smoking-VR cues, and during (time = 5) and after (time = 10) the placebo-VR cues (P < 0.05 for all). A positive association was observed between FTND scores and UTS-raw scores after (time = 10) and following (time = 15) the smoking-VR cues (P < 0.05 for both), with a trend towards an association between FTND scores and UTS-change scores for the after (time = 10) and following (time = 15) smoking-VR cues (P < 0.06 for both).

### Table 1
Demographic and Smoking Characteristics for Smoking-VR and Placebo-VR Treated Participants

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Smoking-VR</th>
<th>Placebo-VR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male (%)</td>
<td>80</td>
<td>100</td>
</tr>
<tr>
<td>Female (%)</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White (Not Hispanic) (%)</td>
<td>60</td>
<td>100</td>
</tr>
<tr>
<td>Hispanic or Latino (%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>African American (%)</td>
<td>40</td>
<td>0</td>
</tr>
<tr>
<td>Other (%)</td>
<td>40</td>
<td>0</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± S.E.M.</td>
<td>36.4 ± 4.7</td>
<td>46.8 ± 3.8</td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± S.E.M.</td>
<td>15.2 ± 1.4</td>
<td>13.2 ± 0.8</td>
</tr>
<tr>
<td>Cigarette Use</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cigarettes per Day</td>
<td>17.6 ± 1.1</td>
<td>21.7 ± 1.7</td>
</tr>
<tr>
<td>Years Smoking</td>
<td>13.9 ± 2.8*</td>
<td>27.2 ± 3.6*</td>
</tr>
<tr>
<td>Exhaled Carbon Monoxide (ppm)</td>
<td>22.0 ± 6.0</td>
<td>16.5 ± 6.0</td>
</tr>
</tbody>
</table>

Values represent mean ± S.E.M.; * = p < 0.05

### Between Group Treatment Outcomes
Smoking-VR CET participants had a significantly higher quit rate than placebo-VR CET participants (Fisher’s exact test, P = 0.015). Smoking-VR CET participants also reported smoking significantly fewer cigarettes per day at the end of treatment than placebo-VR CET participants (t9 = 2.54, P = 0.034). Smoking-VR CET participants had (non-significantly) lower exhaled CO levels at the completion of treatment than placebo-VR CET participants (2.8 ppm vs. 8.5 ppm, respectively) (Figure 3).

### Cigarette Craving During Treatment
A within-subject GLM for repeated measures, including a between-group variable, revealed a significant effect of repeated CET sessions on self-reported UTS-raw scores (F1, 10 = 3.64, P = 0.032); however, no effect of treatment type was observed. An exploratory analysis (using a within subject GLM for repeated measures) revealed a significant effect of time when considering UTS scores provided following each VR exposure (time = 15 and time = 30) in smoking-VR CET treated participants (F1, 4 = 3.64, P = 0.046), but not placebo-VR CET treated participants. The study group as a whole demonstrated a significant reduction in UTS scores from the first to last treatment session (t10 = 3.96, P = 0.003). This effect was also observed in each group independently (P < 0.05).

Figure 2. Self-reported cigarette craving during (time = 5), after (time = 10), and following (time = 15) each cue condition (smoking-VR and placebo-VR) presented in the cue-craving assessment (values represent mean change in UTS score from baseline ± standard error mean for each treatment group).
DISCUSSION
Smoking-VR cues elicited significantly higher levels of overall craving and greater increases in cue-induced craving than placebo-VR cues. Tobacco-dependent smokers treated with smoking-VR CET demonstrated a significantly higher quit rate and reported smoking significantly fewer cigarettes per day at the completion of treatment. Although not significant, smoking-VR treated participants also provided substantially lower exhaled CO levels than placebo-VR treated participants at the end of treatment. All participants reported significant decreases in cigarette craving across treatment, as well as significant reductions in craving from the start to the completion of treatment. Taken together, these preliminary findings establish the potential for smoking-VR CET, in combination with CBT, to be a useful treatment for tobacco dependence.

Previous studies of CET in substance-dependent individuals have used a range of treatment paradigms and outcome variables, leading to varied success (Conklin & Tiffany, 2002). The largest and most well-controlled study to apply CET in tobacco dependence did not demonstrate enhanced smoking cessation rates when combined with CBT (R. Niaura, et al., 1999); however, the current report is distinct since the previous study used CET consisting of participants imagining themselves in smoking situations, which may have accounted for the disparate results.

Relapse to smoking following treatment commonly occurs when a recently abstinent smoker encounters an environment previously associated with smoking (Wikler, 1973). Studies of CET in smokers have, for the most part, been conducted in non-smoking environments (e.g. clinic, laboratory) (Conklin & Tiffany, 2002), which may present a problem since extinction learning is context dependent, and may not generalize across environments (Bouton & Moody, 2004). Furthermore, environments paired with smoking elicit greater cue-induced urges to smoke than environments not paired with smoking (Dols, Willems, van den Hout, & Bittoun, 2000), even in the absence of smoking-related cues (Conklin, 2006; Thewissen, van den Hout, Havermans, & Jansen, 2005). For these reasons, the present study supports the theory that CET must incorporate multiple, context-relevant environments for extinction learning to translate beyond the treatment setting. Some researchers have addressed this issue by treating people with drug dependence in the environment where they use drugs (Dawe, et al., 1993; Kasvikis, Bradley, Powell, Marks, & Gray, 1991). The method used here has potential advantages for practicality and safety. More recently, VR drug cue environments have been applied to CET and demonstrated efficacy in reducing craving and cue-induced brain activation in smokers (J. Lee, et al., 2004; J. H. Lee, Lim, Wiederhold, & Graham, 2005).

Preclinical models of reinstatement have discovered that manipulating intra- and inter-session intervals of extinction learning may reduce cue-associated relapse. Short, repeated presentation of cues, with sufficient time between cue exposures to allow for recovery of responding, increases the rate and duration of extinction learning (Berman & Katzov, 1972; Mackintosh, 1974). Spreading out the intervals between extinction learning sessions to allow responding to reemerge also attenuates spontaneous recovery of extinguished behaviors (Bouton, 1993). Previous studies of CET in smokers have applied long extinction sessions, focusing on singular cues, with short inter-session intervals (Conklin & Tiffany, 2002). In the current study, smoking-VR CET treated participants received twice-weekly CET sessions across eight weeks, with each session including two cue exposures. Appropriate spacing of CET sessions would lead to higher craving during the initial cue exposure in a CET session (i.e. return to responding), followed by

Figure 3. Treatment outcome measures: self-reported cigarettes per day and exhaled CO (ppm) measured at the completion of treatment (values represent treatment group mean value ± standard error mean).
an incremental decrease in craving after each subsequent cue exposure (i.e. re-extinguish responding). Smoking-VR CET treated participants demonstrated significantly greater levels of craving following the first smoking-VR cue exposure than the second exposure across treatment. This difference was greatest during the first half of the CET session, presumably when extinction learning was first developing. Furthermore, this effect was absent in placebo-VR CET treated participants suggesting that this reduction in craving was not attributable to general CET procedures, which were matched between groups.

To our knowledge, previous applications of CET for tobacco dependence did not specifically address lapse episodes during treatment. Following a self-reported lapse in the current study, smoking-VR CET treated participants were exposed to a VR context intended to replicate the environment where the lapse occurred. Although no direct measure was applied to assess the efficacy of this intervention, 80% of smoking-VR treated participants proved able to remain abstinent following abstinence lapses, while all placebo-VR treated participants returned to smoking.

This study had several limitations. Although the observed dropout rate (~27%) is within the expected range, the exclusion of four participants led to a low sample size. Consequently, the study population reported here lacked gender and ethnic diversity, and was not entirely balanced (e.g. placebo-VR CET treated participants reported more years of smoking). Demographic variables such as age (negatively associated with overall craving to smoking-VR and placebo-VR cues) and tobacco dependence (positively associated with overall craving to smoking-VR cues) may have also influenced individual treatment responses. Applying CET as an outpatient treatment constrains the number of controls and measures (e.g. physiological reactivity) that can be taken to assess treatment efficacy, which could enhance extinction learning and abstinence. This lack of control (e.g. time since last cigarette) also led to between subject variability in self-reported cravings during CET sessions, though this method may be more applicable to actual clinical treatment situations.

In conclusion, smoking-related VR cues proved useful in eliciting cue-induced craving and, when applied with the parameters used here, may significantly enhance the efficacy of CET as a treatment for tobacco dependence.

Acknowledgements
Supported by the National Institute on Drug Abuse (A.L.B. [R01 DA20872]; C.S.C. [DA245482]), the Tobacco-Related Disease Research Program (19XT-0135), a Department of Veterans Affairs Type I Merit Review Award, the Richard Metzner Chair in Clinical Neuropsychology (A.L.B.), and the ARCS Foundation. The authors would also like to acknowledge the UCLA Experiential Technology Center for their assistance in building the virtual reality cigarette smoking-related environment.

References


Culbertson et al.


